A new study led by the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute and the University of Gothenburg (Sweden) has identified two new blood biomarkers that better capture early signs of Alzheimer’s to diagnose it early.
It’s about the blood biomarkers p-tau 217 and p-tau231suitable for indicating brain changes related to amyloid protein in people who do not yet show cognitive symptoms, so that it can be detected early if a person already in middle age has a high risk of developing Alzheimer’s.
The study
The investigation, which within the Pasqual Maragall Foundation headed the Barcelonaβeta Brain Research Center (BBRC), has been published in the prestigious journal Nature Medicine. And as leading professors of the international team are Marc Suárez-Calvet, researcher at the Pasqual Maragal Foundation research center and neurologist at Hospital del Mar, and Professor Kaj Blennow, from the University of Gothenburg.
Related news
this find will help drive clinical trials beyond the preclinical phase of Alzheimer’s disease and, in addition, the analysis of biomarkers in blood is a inexpensive and non-invasive procedure with great potential to help the diagnostic process of Alzheimer’s pathology, those responsible have assured in a statement.
To carry out this direct comparison between the main biomarkers, the their behavior in almost 400 participants that are part of the Alfa Study, which has the support of the “la Caixa” Foundation.